McKesson Corporation (NYSE:MCK) is included among the 14 Best Pharma Dividend Stocks to Buy in 2026. On December 10, Deutsche ...

If you are wondering whether McKesson still looks attractive after its strong run, or whether much of the potential upside is ...

The deal will secure part of Cencora's customer base for lucrative cancer drugs. The Conshohocken company also control a ...

McKesson saw strong 2025 growth from GLP-1 tailwinds, but fading momentum, weak margins, and a 21x forward P/E show ...

McKesson Corporation's latest quarterly report presented a nuanced picture for investors. While the healthcare distribution giant comfortably surpassed earni ...

Insights from community oncologists and practice staff uncover strategies to accelerate precision medicine, expand trial access and prepare for technology-driven care IRVING, Texas--(BUSINESS ...

In October 2025, Citius Oncology announced a distribution services agreement with McKesson, making McKesson an authorized distributor of record for LYMPHIR, a newly FDA-approved immunotherapy for ...

CRANFORD, N.J., Oct. 20, 2025 /PRNewswire/ -- Citius Oncology, Inc. ("Citius Oncology") (Nasdaq: CTOR), the oncology-focused subsidiary of Citius Pharmaceuticals, Inc ...

Earlier this week, Cycle Pharmaceuticals announced the launch of PHYRAGO, a new oncology therapy for leukemia, developed with Handa Therapeutics and made exclusively available in the US through ...

McKesson is one of three leading domestic wholesalers of branded, generic, and specialty pharmaceutical products. With over $300 billion in sales, the firm supplies roughly a third of the domestic ...

The MarketWatch News Department was not involved in the creation of this content. McKesson Medical-Surgical to Exclusively Distribute Playhouse MD(TM)'s Character-Driven Medical Devices on Amazon to ...

Narrow-moat McKesson reported third-quarter results that were largely in line with our expectations. Total sales grew 18% year over year to $95.3 billion, driven by strong momentum in the US ...